Steven Rosenberg: The beginning of a new way to use immunotherapy
NCI Center for Cancer Research shard a post LinkedIn:
“Empowering immune systems: While cellular immunotherapies are effective against many blood cancers and melanomas, other kinds of solid tumors have been mostly unresponsive to this type of treatment. But in an ongoing clinical trial led by Steven Rosenberg, researchers have found that with a new approach, patients’ immune cells can be programmed to shrink metastatic colon cancer, too.
“The methodology that we’ve developed works,” says Rosenberg, whose group at the National Cancer Institute of the NIH has pioneered these innovative types of treatments for decades. “We’re concentrating now on solid epithelial cancers – common cancers that occur in the solid organs of the body. Ninety percent of everyone who dies of cancer dies of these. This is the beginning of a new way to use immunotherapy.”
Read more about this research milestone.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023